CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts

E Marangoni; N Lecomte; L Durand; G de Pinieux; D Decaudin; C Chomienne; F Smadja-Joffe; M-F Poupon

doi:10.1038/sj.bjc.6604953

CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts

Br J Cancer. 2009 Mar 24;100(6):918-22. doi: 10.1038/sj.bjc.6604953. Epub 2009 Feb 24.

Authors

E Marangoni¹, N Lecomte, L Durand, G de Pinieux, D Decaudin, C Chomienne, F Smadja-Joffe, M-F Poupon

Affiliation

¹ Translational Research Department, Institut Curie, 75010 Paris, France. Elisabetta.Marangoni@curie.fr

Abstract

CD44 is a marker of tumour-initiating cells and is upregulated in invasive breast carcinoma; however, its role in the cancer progression is unknown. Here, we show that antibody-mediated CD44-targeting in human breast cancer xenografts (HBCx) significantly reduces tumour growth and that this effect is associated to induction of growth-inhibiting factors. Moreover, treatment with this antibody prevents tumour relapse after chemotherapy-induced remission in a basal-like HBCx.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Monoclonal / therapeutic use*
Female
Humans
Hyaluronan Receptors / analysis
Hyaluronan Receptors / immunology
Hyaluronan Receptors / physiology*
Mammary Neoplasms, Experimental / chemistry
Mammary Neoplasms, Experimental / drug therapy*
Mammary Neoplasms, Experimental / pathology
Mice
Neoplasm Recurrence, Local / prevention & control*
Xenograft Model Antitumor Assays

Substances

Antibodies, Monoclonal
Cd44 protein, mouse
Hyaluronan Receptors